A well established expert in his field, Dr. Reder has written or contributed to numerous publications on pharmaceutical and medical topics throughout his career.

Review Articles, Chapters, Books

  1. Reder RF, Rosen MR: The role of the sympathetic nervous system in sudden cardiac death.  Drug Therapy 8:41-48, 1978.
  2. Rosen MR, Hordof AJ, Reder RF, Danilo P Jr: Age-related and disease-related changes in cardiac electrophysiologic properties.  From Cardiac Arrhythmias: Electrophysiology, Diagnosis and Management, Narula, O (Ed), William and Wilkins, Baltimore, pp 32-39, 1979.
  3. Reder RF, Rosen MR: Basic Electrophysiologic Principles: Application to Treatment of Dysrhythmias.  In Pediatric Cardiac Dysrhythmias, Gillette PC and Garson A (Eds), Grune and Stratton, NY, pp 121-143, 1981.
  4. Rosen MR, Reder RF: Does Triggered Activity Have a Role in the Genesis of Cardiac Arrhythmias?  Ann Int Med 94:794-801, 1981.
  5. Reder RF and Rosen MR: Mechanisms of cardiac arrhythmias.  Cardiovasc Rev Reports 2:1007-1012, 1981
  6. Reder RF, Rosen MR: Delayed after depolarizations and clinical arrhythmokinesis.  In Normal and Abnormal Conduction in the Heart, Paes de Carvalho A, Hoffman BF and Lieberman M (Eds), Futura Publishing, Mount Kisco, NY, 1982, pp 449-460.
  7. Rosen MR, Reder RF: Electrophysiology of the fetal and neonatal heart.  In Perinatal Cardiovascular Function, Gootman N and Gootman PM (Eds), Marcel Dekker, Inc, NY, pp 201-225, 1983.
  8. Kupersmith J, Bunt PJ, Reder RF: Newer antiarrhythmic drugs.  Primary Cardiology, Supplement, No 2, pp 164-167, 1983.
  9. Kupersmith J, Reder RF: Amiodarone: A Review.  Primary Cardiology 10(7): 116-126, 1984.
  10. Kupersmith J, Reder RF, Slater, W: New antiarrhythmic drugs.  Cardiovasc Rev Rep 6(1):35-56, 1985.
  11. Reder RF, Binah O, Danilo P Jr: Autonomic effects in the developing heart.  In Developmental Neurobiology of the Autonomic Nervous System, Goodman PM (Ed), Humana Press, Inc, Clifton, NJ, pp 193-210, 1986.
  12. ​Ripa S, Bruno N, Reder R, Casillas R, and Roth R I : Clinical Applications of Povidone-Iodine as a Topical Antimicrobial.  In Handbook of Topical Antimicrobials,  Daryl S. Paulson (Ed), Marcel Dekker, Inc.  pp 472, September 2002.

Original Articles

  1. Reder RF, Dimich I, Steinfeld, L, Litwak RS: Left Ventricle to aorta valved conduit for relief of diffuse left ventricular outflow tract obstruction.   Am J Cardiol 39:1068-1072, 1977.
  2. Reder RF, Yeh HC, Dimich I, Steinfeld L: Serial echocardiography of the aortic valve in bacterial endocarditis - a case report.  Mt Sinai J Med 44:521-526, 1977.
  3. Steinfeld L, Dimich I, Reder R, Cohen ML, Alexander H: Sphygmomanometry in the pediatric patient.  J Pediatr 92:934-938, 1978.
  4. Reder RF, Dimich I, Cohen ML, Steinfeld L: Evaluating indirect blood pressure techniques - a comparison of three systems in infants and children.  Pediatr 62:326-330, 1978.
  5. Rosen MR, Reder RF, Hordof AJ, Davies M, Danilo P: Age-related Changes in Purkinje fiber action potentials of adult dogs.  Circ Res 43:931-939, 1978.
  6. Nichols EA, Reder RF: Familial mediterranean fever - a case report.  Am J Dis Child 132:1209-1210, 1978.
  7. Reder RF, Danilo P, Rosen MR: Effects of pirmenol HC1 on electrophysiologic properties of cardiac Purkinje fibers.  Eur J Pharmacol 61:321-333, 1980.
  8. Danilo P, Hordof AJ, Reder RF, Rosen MR: Effects of verapamil on electrophysiologic properties of blood superfused cardiac Purkinje fibers.  J Pharmacol Exp Ther 213:222-227, 1980.
  9. Reder RF, Miura DS, Danilo P, Rosen MR: The electrophysiologic properties of normal neonatal and adult canine cardiac Purkinje fibers.  Circ Res 48:658-668, 1981.
  10. Reder RF, Yeh HC, Steinfeld L: Aneurysm of the interatrial septum causing pulmonary venous obstruction in an infant with tricuspid atresia.  Am Hear J 102:786-789, 1981.
  11. Dangman KH, Danilo P, Hordof AJ, Mary-Ravine L, Reder RF, Rosen MR: Electrophysiologic characteristics of human ventricular and Purkinje fibers.  Circulation 65:362-368, 1982.
  12. Reder RF, Brown EG, DeAsla RA, Jurado RA: Thermal skin burns in children from a CO2 analyzer.  Ann Thorac Surg 35:329-330, 1983.
  13. Reder RF, Camunas JL, Shiang H, Danilo P, Mindich BP: Experimental replacement of canine pericardium.  Mt Sinai J of Med 50:491-497, 1983.
  14. Danilo P Jr, Reder RF, Legato M, Binah O: Fetal canine cardiac Purkinje fibers: electrophysiology and ultrastructure.  Am J Physiol 246:H250-H260, 1984.
  15. Reder RF, Raucher H, Cesa M, Mindich BP: Purulent pericarditis caused by Streptococcus Anginosus - Constellatus - A case report.  Mt Sinai J of Med Vol 51, No 3, June, 1984.
  16. Reder RF, Danilo P Jr, Rosen MR: Developmental changes in alpha adrenergic effects on canine Purkinje fiber automaticity.  Dev Pharmacol Ther 7:94-108, 1984.
  17. Reder RF, Mindich B, Halperin J, Litwak RS, Kupersmith J: Acute effects of oral labetalol on myocardial conduction after coronary artery bypass grafting.  Clin Pharmacol Ther 35:454-460, 1984.
  18. Robinson RB, Reder RF, Danilo P Jr: Preparation and electrophysiological characterization of cardiac cell cultures derived from the fetal canine ventricle.  Dev Pharmacol Ther 7:307-318, 1984.
  19. Halperin JL, Mindich BP, Rothlauf EB, Reder RF, Litwak RS, Kupersmith J: Effects of labetalol on limb hemodynamics in patients following coronary artery bypass graft surgery.  Br J Clin Pharmacol 21:537-542,1986.
  20. Moak JP, Reder RF, Danilo P Jr, Rosen MR: Development changes in the interactions of cholinergic and beta-adrenergic agonists on electrophysiologic properties of canine cardiac Purkinje fibers.  Pediatr Res 20(7):613-618, 1986.
  21. Thadani U, Prasad R, Hamilton SF, Karpow SA, Reder RF, Teague SM: Isosorbide-5-Mononitrate in angina pectoris: dose response, plasma concentrations and duration of effects following acute therapy.  Clin Pharmacol Ther 42:58-65, 1987.
  22. Thadani U, Prasad R, Hamilton SF, Voyles W, Doyle R, Karpow S, Reder RF, Teague SM: Usefulness of twice-daily isosorbide-5-mononitrate in preventing development of tolerance in angina pectoris.  Am J Cardiol 60:477-482, 1987.
  23. Cubberley RB, Thomas S, Charatan M, Zolli B, Reder RF: Effects of verapamil in black hypertensive patients.  Cardiovasc Rev Reports 9(5):55-58, 1988.
  24. McMahon FG, Reder RF, for the Verapamil SR Study Group:  The relationship of dose to the antihypertensive response of verapamil-sustained release in patients with mild to moderate essential hypertension.  J Clin Pharmacol 29:1003-1007, 1989.
  25. Hernandez M, Reder R, Marinchak RA, Rials SJ, Kowey PR: Propafenone for malignant ventricular arrhythmia: An analysis of the literature.  Am Heart J 121:4(1):1178-1184, 1991.
  26. Kaiko RF, Grandy RP, Reder, RF, Goldenheim PD, Sackler RS: A bioequivalence study of oral controlled-release morphine using naltrexone blockade.  J Clin Pharmacol 35:499-504, 1995.
  27. Bashaw D, Kaiko RF, Grandy RP, Reder RF, Goldenheim PD, Relative bioavailability of controlled release oral morphine sulfate during naltrexone blockade.  Int J Clin Pharmacol Thera 33(9):524-529, 1995.
  28. Kaiko RF, Benziger, DP, Fitzmartin, RD, Burke, BE, Reder, RF, Goldenheim PD: Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone.  Clin Pharmacol Thera 59:52-61, 1996.
  29. Reder RF, Oshlack B, Jahanara MS, Miotto JB, Benziger DD, Kaiko, RF:  Steady-state bioavailability of controlled-release oxycodone in normal subjects.  Clin Thera 18(1):95-105, 1996.
  30. Benziger DP, Kaiko RF, Miotto JB, Fitzmartin RD, Reder RF and Chasin M:  Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution. J Pharmaceu Sci 85(4):407-410, 1996.
  31. Sunshine A, Olson NZ, Colon, A, Rivera J, Kaiko, RF, Fitzmartin, RD, Reder, RF, and Goldenheim, PD:  Analgesic efficacy of controlled-release oxycodone in postoperative pain.  J Clin Pharmacol 36:595-603, 1996.
  32. Mandema JW, Kaiko RF, Oshlack B, Reder RF, Stanski DR; Characterization and validation of a pharmacokinetic model for controlled-release oxycodone.  Br J Clin Pharmacol 42:747-756, 1996
  33. Kaplan R, Parris, WCV, Citron, ML, Zhukovsky, D, Reder, RF, Buckley, BJ, Kaiko, RF: comparison of controlled-release oxycodone tablets in patients with cancer pain. J Clin Oncology 16:3230-3237, 1998.
  34. Parris, WCV, Johnson, BW, Croghan, MK, Moore, MR, Khojasteh, A, Reder, RF, Kaiko, RF, Buckley BJ:  the use of controlled-release oxycodone for the treatment of chronic cancer pain:  a randomized, double-blind study.  J Pain and Symptom Management 16:205-211, 1998
  35. Citron,ML, Kaplan,R, Parris,WCV, Croghan,MK, Herbst,LH, Rosenbluth,RJ, Slagle,NS, Buckley,BJ, Kaiko,RF.  Long-Term Administration of Controlled-Release Oxycodone Tablets for the Treatment of Cancer Pain.  Cancer Investigation, 16(8), 562-571, 1998.
  36. Mucci-LoRusso, P, Berman, BS, Silberstein, PT, et al.  Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain:  a randomized, double-blind, parallel-group study.  Eur J Pain  2/3:239-249, 1998.
  37. Roth, SH, Reder, RF.  The role of opioids in the treatment of osteoarthritis.  Resident & Staff Physician 44(12):31-36, 1998.
  38. Kaplan, R, Parris, WCV, Citron, ML, Zhukovsky, D, Reder, RF, Buckley, BJ, Kaiko, RF.  Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain.  Journal Clinical Oncology 1998; 16:3230-7.
  39. Roth, SH, Reder, RF.  El papel de los opiáceos en el tratamiento de la osteoarthritis.  Mundo Medico 26 (293): 9-16, 1999.
  40. Salzman, RT, Roberts, MS, Wild, J, Fabian, C, Reder, RF, Goldenheim, PD.  Can a controlled-release oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control?  Journal of Pain and Symptom Management 18(4): 271-279, 1999.  
  41. Stambaugh JE, Reder RF, Stambaugh MD, Stambaugh H and Davis M: Double-blind, randomized Comparison of the analgesic and pharmacokinetic profiles of controlled and immediate-release oral oxycodone in cancer pain patients.  J Clin Pharmacol 2001; 41:500-506
  42. Reder, RF: Opioid formulations: tailoring to the needs in chronic pain.  European Journal of Pain (2001) 5 (Suppl. A): 109-111
  43. Cone, EJ, Fant, RV, Rohay, JM, Caplan, YH, Ballina, M, Reder, RF, Spyker, D, Haddox, JD: Oxycodone Involvement in Drug Abuse Deaths: A DAWN-Based Classification Scheme Applied to an Oxycodone Postmortem Database Containing Over 1000 Cases.  Journal of Analytical Toxicology; Vol, 27, March 2003; pp. 57-67 
  44. Roth, SH, Reder, RF, Carrig, B:  Oxycodone Therapy for the Treatment of Pain Associated with Osteoarthritis   Clinical Geriatrics; (2003) 11 (8):18-30
  45. Cone, EJ, Fant, RV, Rohay, JM, Caplan, YH, Ballina, M, Reder, RF, Haddox, JD:  Oxycodone Involvement in Drug Abuse Deaths. II. Evidence for Toxic Multiple Durg-Drug Interactions.  Journal of Analytical Toxicology, (2004) 28 (7):616-624
  46. Grosset AB, Roberts MS, Woodson ME, Shi M, Swanton RE, Reder RF, and Buckley B. Comparative  efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized clinical trials.  Journal Pain and Symptom Management, (2005) 29(6):584-594

​Abstracts

  1. Dimich I, Reder RF, Steinfeld L: Cardiovascular effects of maternal methadone addiction in the newborn.  Pediatric Res II (4):338, 1977.
  2. Steinfeld L, Reder RF, Dimich I: Evaluating indirect blood pressure techniques - A comparative study.  Pediatric Res II(4):400, 1977.
  3. Steinfeld L, Reder RF, Dimich I: Evaluating indirect blood pressure techniques - A comparative study.  Circulation 55 & 56 III-20, 1977.
  4. Reder RF, Danilo P, Rosen MR: Effects of CI845 on canine Purkinje fibers with fast and slow response action potentials.  The Pharmacologist 20(3):149, 1978.
  5. Reder RF, Hordof A, Davies M, Danilo P, Rosen MR: Age-related changes in adult canine cardiac Purkinje fiber action potentials.  Circulation 58:II-46, 1978.
  6. Reder RF, Danilo P, Rosen MR: Age-related changes in effects of tetrodotoxin on cardia Purkinje fibers.  Fed Proc 38(3):880, 1979.
  7. Reder RF, Danilo P, Rosen MR: Effects of Pirmenol hydrochloride on blood-superfused canine cardiac Purkinje fibers.  The Pharmacologist 21:200, 1979.
  8. Danilo P, Reder RF, Mill J, Petrie R: Developmental changes in cellular electrophysiologic characteristics and catecholamine content of fetal heart.  Circulation 59 & 60 (Suppl II) II-50, 1979.
  9. Danilo P, Reder RF, Hordof AJ, Rosen MR: Age-related changes in cellular electrophysiologic properties.  Bull NY Acad Med 55:412-413, 1979.
  10. Reder RF: Age-related changes in the electrophysiologic properties of neonatal and adult canine cardiac Purkinje fibers.  Trends in Pharmacologic Sci 1(5):Jan, 1980.
  11. Reder RF, Miura D, Danilo P, Rosen MR: The electrophysiologic properties of normal neonatal and adult canine cardiac Purkinje fibers.  Am J Cardiol 45:431, 1980.
  12. Reder RF: Effects of maturation on the slow, inward calcium current in the canine heart.  Pediatric Cardiol 1:170, 1979/1980.
  13. Reder RF, Danilo P, Rosen MR: Developmental changes in -adrenergic effects on automaticity.  Circulation 62:III-55, 1980.
  14. Rosen MR, Dangman K, Danilo P, Hoffman B, Hordof A, Mary-Rabine L, Reder RF, Reemtsma K: Electrophysiology of human Purkinje and ventricular fibers.  Circulation 62:III-56, 1980.
  15. Reder RF, Danilo P: Effects of tetrodotoxin on fetal canine cardiac Purkinje fibers.  Fed Proc 40:469, 1981.
  16. Robinson RB, Frame LH, Reder RF, Danilo P: Electrophysiologic characteristics of canine cardiac monolayer cultures.  Fed Proc 40:562, 1981.
  17. Danilo P, Reder RF, Garlick P, Rosen MR, Mill J: Effects of sympathectomy on the response to catecholamine of canine Purkinje fibers.  Fed Proc 40:414, 1981.
  18. Steinfeld L, Rezende J, Nazarian H, Arnon R, Reder RF: Persistent fetal circulation studied by contrast echocardiography.  Pediatr Cardiol 2(2):175, 1982.
  19. Moak JP, Rosen MR, Reder RF, Danilo P Jr: Interactions of isoproterenol and acetylcholine on neonatal and adult canine cardiac Purkinje fibers.  Circulation 68:III-329, 1983.
  20. Halperin JL, Rothlauf EB, Mindich BP, Reder RF, Litwak RS, Kupersmith J: Limb hemodynamic effects of labetalol following coronary bypass surgery.  Clinical Res 32:173A, 1984.
  21. Thadani U, Prasad R, Hamilton S, Karpow S, Reder RF, Teague S: Isosorbide-5-mononitrate in angina pectoris: Does BID dosing schedule prevent development of tolerance?  Clin Invest Med 9:B55, 1986.
  22. Thadani U, Prasad R, Hamilton S, Karpow S, Reder R, Teague S: Isosorbide-5-mononitrate in angina pectoris: Does BID dosing schedule prevent development of tolerance?  Circulation 74(Suppl II):II-137, Oct 1986.
  23. Thadani U, Prasad R, Hamilton S, Karpow S, Reder R, Teague S: Isosorbide-5-mononitrate in angina pectoris: Does BID dosing schedule prevent development of tolerance?  Presented to the 9th Asian-Pacific Congress of Cardiology, 1986.
  24. Thadani U, Prasad R, Hamilton S, Voyles W, Teague S, Doyle R, Karpow S, Reder R: Duration of effects of Isosorbide-5-mononitrate in angina pectoris.  Clin Pharmacol Ther 41:183, 1987.
  25. Thadani U, Prasad R, Hamilton S, Voyles W, Doyle R, Karpow S, Reder RF, Teague S: Duration of effects of Isosorbide-5-mononitrate in angina pectoris.  JACC Vol 9, p 134A, 1987.
  26. Turek D, Reder R, Karpow S, Baird W: Pharmacokinetic/pharmacodynamic comparison of low and high dose hydromorphone and morphine oral solutions in acute post operative pain.  Clin Pharmacol Ther 41:229, 1987.
  27. Deedwania P, Bittar N, Reder RF, Karpow S, Thadani U: Nitrate Tolerance: Failure of twice daily therapy with isosorbide-5-mononitrate in improving exercise tolerance throughout the dosing intervals.  Presented at Xth International Congress of Pharmacology, Sydney, Australia, August 23-28, 1987.
  28. Jain AK, McMahon FG, Reder RF, Smith G: A placebo-controlled study of an oral solution of 5 and 10 mg of hydromorphone HC1 in post operative pain.  Clin Pharmacol Ther 45(2):175, 1989.
  29. Deedwania P, Bittar N, Reder R, Karpow S, Thadani U: Nitrate tolerance despite high plasma concentrations and 12 hourly treatments with Isosorbide-5-mononitrate.  Presented at the IV World Conference on Clinical Pharmacology & Therapeutics, Heidelberg, Germany July 23-28, 1989.
  30. Thadani U, Bittar N, Doyle R, Karpow S, Reder RF: Nitrate tolerance: Do "critical" trough plasma levels exist to prevent tolerance?  Circulation 80:11-215, 1989.
  31. Reder RF: Relationship of dose to antihypertensive response of verapamil-sustained release.  Clin Res Vol 37, No. 3, p 855A, 1989.
  32. Reder RF: Relationship of dose to antihypertensive response of verapamil-sustained release (V-SR).  J Clin Pharmacol 29:833, 1989.
  33. Hernandez M, Reder R, Marinchak RA, Rials SJ, Kowey PR: A literature-based meta-analysis of propafenone for malignant ventricular arrhythmia.  Clin Res Vol 38, No 3, p 782A, Oct 1990.
  34. Reder R, Fitzmartin R, Citron M, Spaulding M: Interchangability of various dosage strengths of controlled-release morphine (MS Contin®) in patients with cancer related pain. Proceedings of ASCO Vol.12:448, 1993.
  35. Levy MH, Fitzmartin R, Reder R: Comparison of immediate versus controlled release morphine (MS Contin) in the long term management of cancer related pain. Proceedings of ASCO Vol. 12:455, 1993.
  36. Bouchard J, Reder R, Slagle S, Kaiko R, Cronin C, Goldwater D, Solomon D: Factors in conversion of cancer patients from oral analgesia to patient controlled analgesia (PCA) devices. Proceedings of ASCO Vol. 12:459, 1993.
  37. Glajchen M, Blum D, Fitzmartin R, Reder R: Clinical guidelines for oncologist-patient communication in cancer pain management. Proceedings of ASCO Vol. 12:459, 1993.
  38. Lazarus H, Reder R, Slywka J, Tan C, Fitzmartin R:Survey of clinical experience with controlled-release morphine (MS Contin®) in cancer patients. Proceedings of ASCO Vol. 12:466, 1993.
  39. Reder RF, Kaiko R, Wright C:Association of onset of typical opiate side effects with plasma morphine concentrations. Proceedings of College on Problems of Drug Dependence, Inc., Fifty-fifth Annual Scientific Meeting, June 12-17, 1993.
  40. Kaiko RF, Reder RF, Grandy RP, Fitzmartin  RD, Goldenheim PD:Controlled-release oral morphine (MS Contin tablets, MSC) for postburn analgesia in adult and pediatric patients.  Proceedings of Intern. Association for the Study of Pain, 7th World Congress on Pain, August 21-27, 1993, p. 312. 
  41. Reder RF, Kaiko R, Kisicki J:The relationship of plasma morphine concentrations to typical opiate side effects in normal volunteers when oral morphine is administered with and without naltrexone. Proceedings of International Association for the Study of Pain, 7th World Congress on Pain, August 21-27, 1993, p.535.
  42. Glajchen, Blum, Fitzmartin, Reder:Non-medical aspects of cancer pain relief:  Converting obstacles into practice interventions.  American Pain Society, Orlando, Florida, November 4-7, 1993, p. A-78.
  43. Glajchen, Blum, Calder, Fitzmartin, Reder:Refining a role for social work within the multi-discipinary pain team.  American Pain Society, Orlando, Florida, November 4-7, 1993, p. A-79.
  44. Cooper, SA, Witte, JF, Mooar, PA, Fitzmartin, RD, Slywka, J, Reder, RF, Kaiko, RF, Grandy, R:Comparison of analgesic potency and safety of two controlled-release oral morphine tablets in orthopedic post-surgical pain.  American Pain Society, Orlando, Florida, November 4-7, 1993, p. A-85.
  45. Baker, DK, Buckley, BJ, Reder, RF, Tan, CT:Reduction of cancer related pain in children using controlled release morphine.  Third International Symposium on Pediatric Pain, Philadelphia, PA, June 8, 1994.
  46. Grandy R, Reder R, Fitzmartin R, Benziger D, Kaiko R:Steady-State pharmacokinetic comparison of controlled-release oxycodone (OxyContin) tablets vs. oxycodone oral liquid.  Journal Clin Pharmacol; Vol. 34:1015, October 1994.
  47. Mandema JW, Kaiko RF, Oshlack B, Reder RF, Stanski:Pharmacokinetic model for a new oral controlled release formulation of oxycodone.  Anesthesiology, Vol 81, No. 3A, September, 1994.
  48. Benziger DP, Thomas G, Miotto J,  Grandy R, Kaiko R , Reder R:Bioavailability and pharmacokinetics of controlled-release oxycodone (OxyContin) tablets vs. oxycodone oral liquid.  American Pain Society Program Book, 1994;A-121,#94732.
  49. Kaiko R, Grandy R, Benziger D, Oshlack B, Fitzmartin R, Thomas G, Reder R, Goldenheim P:PK/PD relationships of controlled-release oxycodone and metabolites in normal volunteers.  American Pain Society Program Book, 1994;A-123,#94736.
  50. Reder R, Kaiko R, Grandy R,  Fitzmartin R , Bashaw D:Steady-state bioavailability comparison of controlled release oxycodone (OxyContin) tablets vs. oxycodone oral liquid. American Pain Society Program Book, 1994;A-35,#94604.
  51. Roth S, Burch F, Fleischmann R, Iwan T, Fitzmartin R, Kaiko R, Benzigner D, Reder R, Lacouture P: PK/PD relationships in patients receiving controlled-released (CR) oxycodone.  Clinical Pharmacology & Therapeutics, Vol. 57(2):165, February, 1995.
  52. Lacouture PG, Iwan T,  Fitzmartin R, Kaiko R, Benziger D,  Reder R, Goldenheim P:PK/PD relationships in patients receiving controlled-release (CR) oxycodone.  1st Scientific Meeting of the European Federation of IASP Chapters, 5/18-21, 1995.
  53. Reder R, Grandy R, Lacouture PG, Fitzmartin  R, Kaiko R:PK/PD relationships in normals and patients.  College on Problems of Drug Dependence, June 1995.
  54. Benziger DP, Levy SA, Fitzmartin  RD, Reder RF:Dose proportionality of 10, 20 and 40 mg controlled-release oxycodone hydrochloride tablets (OxyContin).  American College of Clinical Pharmacy, Washington, DC, August 8-9, 1995.  Pharmacotherapy 1995; 15(3):391, #188.
  55. Kaplan R, Parris W, Croghan M, Citron M, Herbst L, Rosenbluth R, Slagle S, Buckley B, Reder R: Decrease in opioid-related adverse experiences (AE) during chronic therapy with controlled-release oxycodone (Oxycr) in cancer pain patients. American Pain Society 14th Annual Scientific Meeting, Los Angeles, CA, p. A-146 (Abst. #95882) Program Book,  November 9-12, 1995.
  56. Reder RF, Fitzmartin RD:Physician survey of attitudes about controlled-release oxycodone (Oxycr), American Pain Society 14th Annual Scientific Meeting, Los Angeles, CA, p. A-144 (Abst. #95878) Program Book,  November 9-12, 1995.
  57. Grandy R, Fitzmartin  RD, Kaiko R, Reder R, Benziger D:Pharmacokinetics and pharmacodynamics of controlled-release oxycodone (OxyContin™) in healthy elderly and young adult volunteers, American Pain Society 14th Annual Scientific Meeting, Los Angeles, CA, p. A-145 (Abst. # 95880) Program Book,  November 9-12, 1995.
  58. Benziger DP, Kaiko R, Fitzmartin R, Reder R:Bioequivalency and pharmacokinetics of controlled-release oxycodone tablets (OxyContin™), American Pain Society 14th Annual Scientific Meeting, Los Angeles, CA, p A-145 (Abst. #95879)  Program Book,  November 9-12, 1995.
  59. Fitzmartin RD, Reder RF: Stigma associated with opioid therapy for pain:  results of a health care provider survey, American Pain Society 14th Annual Scientific Meeting, Los Angeles, CA , p. A-144 (Abst. #95887) Program Book,  November 9-12, 1995.
  60. Reder RF, Grandy RP, Lacouture PG, Fitzmartin RD, Kaiko, RF: Oxycodone Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships in Normals and Patients, NIDA Research Monograph 162, 1996, p. 273.
  61. Kaplan R, Parris WCV, Citron ML, Zhukovsky DS, Khojasteh A, Buckley BJ, Tan C, Reder, RF, Kaiko, RF: Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain, a double-blind study, 8th World Congress on Pain Meeting, August 17-22, 1996, Vancouver, British Columbia, Canada, 58, p. 20.
  62. Parris WCV, Johnson BW Jr., Croghan MK, Moore MR, Khojasteh A, Reder RF, Slagle NS, Buckley BJ: Therapeutic evaluation of controlled-release oxycodone (OxyContin™) tablets in the treatment of chronic cancer pain: a double-bind study, 8th World Congress on Pain Meeting, August 17-22, 1996, Vancouver, British Columbia, Canada, 59, p. 20.
  63. Citron ML, Croghan MK, Parris WCV, Buckley BJ, Slagle NS, Reder R: Use of rescue analgesic for breakthrough pain in chronic cancer patients, 8th World Congress on Pain Meeting, August 17-22, 1996, Vancouver, British Columbia, Canada, 60, p. 21.
  64. Berger A, Holme C, Saberski, L, Zelterman D, Davis LE, Tan  C, Reder R: Controlled-release oral morphine (MS Contin® Tablets) versus fentanyl transdermal system (Duragesic®) for the outpatient treatment of cancer pain, 8th World Congress on Pain Meeting, August 17-22, 1996, Vancouver, British Columbia, Canada, 61, p. 21.
  65. Narcessian EJ, Clark G, Reder RF: Validation study of the controlled-release oxycodone (OxyContin™) tablet package insert prior to FDA approval for marketing, 8th World Congress on Pain Meeting, August 17-22, 1996, Vancouver, British Columbia, Canada, 170, p. 53.
  66. Reder R, Lacouture P, Kaiko R, Fitzmartin R, Goldenheim P, Salzman R, Roberts M: Ease of titration to stable pain control in chronic pain patients with controlled-release oral oxycodone (OxyContin™) tablets, 8th World Congress on Pain Meeting, August 17-22, 1996, Vancouver, British Columbia, Can., 171, p. 53.
  67. Goldenheim P, Ingber E, Reder R, Fitzmartin R, Benziger D, Cheng C, Andrews J, Kaiko R: Predictability and consistency of peak (P) and trough (T) plasma oxycodone with different doses and patient populations after q6h oxycodone (IR) and q12h OxyContin™ tablets (CR), 8th World Congress on Pain Meeting, August 17-22, 1996, Vancouver, British Columbia, Canada, 226, p. 286.
  68. Fitzmartin R, Iwan T, Lacouture PG, Reder R, Kaiko R: Safety of controlled-release (CR) oxycodone (OxyContin™ tablets) in elderly patients:  a meta-analysis, 8th World Congress on Pain Meeting, August 17-22, 1996, Vancouver, British Columbia, Canada, 276, p. 519.
  69. Reder R, Lockhart E, Shi M: A comparison of the duration of adverse drug effects (ADEs) associated with controlled-release oxycodone (OxyContin™) and immediate-release oxycodone (IR), 15th Annual Scientific Session, American Pain Society, November 14-17, 1996, p. A-66.
  70. LoRusso P, Berman B, Silberstein P, Mullane M, Citron M, Weinstein S, Reder R, Smith M, Buckley B, Shi M: Comparison of controlled-release oxycodone (OxyContin™) tablets to controlled-release morphine (MS Contin®) in patients with cancer pain, 15th Annual Scientific Session, American Pain Society, November 14-17, 1996, p. A-67.
  71. Reder R, Buckley B, Shi M.  Use of the FACT-G in the Comparison of OxyContin® to MS Contin® Tablets in the treatment of cancer pain., 3rd Annual Meeting, American Academy of Pharmaceutical Physicians, December 8-10, 1996.
  72. Stambaugh JE, Reder RF, Stambaugh M, Davis M:  Double-Blind, Randomized, Two-Period Crossover Efficacy and Pharmacokinetic Comparison of Immediate-Release Oxycodone (IR) and Controlled-Release Oxycodone (CR) in Cancer Patients with Pain. Clin Pharmacol Ther 1997; 61(2); 197.
  73. Weinstein S, Lo Russo P, Berman B, Silberstein P, Mullane M, Citron M and Reder R.  Controlled-release oral oxycodone (Oxycontin®) compared to controlled-release morphine (MS Contin®) in  patients with cancer pain.  Fifth Congress of the European Association for Palliative Care; 10-13, September 1997, London S30-S31.
  74. Reder RF, Stambaugh JE, Stambaugh M and Davis M.: Double-Blind, Randomized, Two-Period Crossover Efficacy and Pharmacokinetic Comparison of Immediate-Release Oxycodone (IR) and Controlled-Release Oxycodone (CR) in Cancer Patients with Pain Fifth Congress of the European Association for Palliative Care; 10-13 September 1997, London S31.
  75. Kaiko R, Lockhart E, Grandy R, Reder R.  Bioequivalency of an 80 mg Controlled-Release Oxycodone (OxyContin®) Tablet compared to two 40 mg CR Oxycodone Tablets. Fifth Congress of the European Association for Palliative Care; 10-13, September 1997, London S33.
  76. Reder, RF, Kaiko RF, Lockhart E, Benziger D, Slagle S, Goldenheim P.  Controlled-Release Oral Oxycodone (OxyContin®) Tablets for the Control of Cancer Pain.  II Congress of the European Federation of IASP Chapters (EFIC) 23-27 September 1997, Barcelona, Spain. p. 365
  77. Reder R, Shi M, Lockhart E, Kaiko R.  Oxycodone may be Associated with a Lower Incidence of Hallucinations than Morhpine. II Congress of the European Federation of IASP Chapters (EFIC) 23-27 September 1997, Barcelona, Spain. p. 366.
  78. Reder, R, Shi, M, Kaiko, R.  Relationship Between Pain Intensity Scores Captured on a Categorical Scale (CAT) Compared to Those on a Visual Analogue Scale (VAS).   16th Annual Scientific Meeting American Pain Society 23-26 October 1997, New Orleans, LA, p. 121.
  79. Reder, RF, Buckley, B.  Open Label Clinical Use Study of Controlled-Release (CR) Oxycodone Tablets (OxyContin) Administered Orally Every 12 hours for the Management of Pain.  17th Annual Scientific Meeting American Pain Society 5-8 November 1998, San Diego, CA,  p. 129.
  80. LoRusso, P, Reder, RF, Buckley, B, Shi, Ming Gao.  The Effects of Oral Controlled-Release Morphine and Oxycodone on Cancer-Related Neuropathic Pain. 17th Annual Scientific Meeting American Pain Society 5-8 November 1998, San Diego, CA, p. 130.
  81. Buckley, B, Reder, RF.  Controlled-Release (CR) Oxycodone Tablets (OxyContin) Administered Orally Every 12 Hours:  Patients with Neuropathic Pain. 17th Annual Scientific Meeting American Pain Society 5-8 November 1998, San Diego, CA, p. 130.
  82. Kori, SH, Barreras, R, Lahvis, F, Reder, RF, Seidler, C.  The Therapeutic Use of Controlled-Release (CR) Oral Oxycodone (OxyContin®) in Opioid Naïve Patients.  9th World Congress on Pain, August 22-27, 1999, Vienna, Austria, p. 325.
  83. Reder, RF, Shi, M.  Safety and Efficacy of Controlled-Release Oral Oxycodone Doses Greater than 80 mg per day.  9th World Congress on Pain, August 22-27, 1999, Vienna, Austria, p. 328.
  84. Lacouture, PG, Iwan, T, Rosen, SI, Reder, RF.  Dosing Patterns with Long-Term Opioid Treatment in Patients with Osteoarthritis Pain. 9th World Congress on Pain, August 22-27, 1999, Vienna, Austria, p. 343.
  85. Rosen, SI, Lacouture, PG, Hopf, K., Iwan, T., Reder, RF, Kaiko, RF.  Treatment of Osteoarthritis Pain with Around-The-Clock Opioids:  The Effect of Concomitant Nsaid Use. 9th World Congress on Pain, August 22-27, 1999, Vienna, Austria, p. 344.
  86. Shi, M, Lacouture, PG, Reder, RF.  Acute Discontinuation of Chronic Opioid Therapy:  A Placebo-Controlled Evaluation. 9th World Congress on Pain, August 22-27, 1999, Vienna, Austria, p. 345.
  87. Wright, C, Reder, R, Ballal, S.  Meta-Analysis Comparison of Safety of Controlled-Release (CR) Oxycodone (OxyContin® Tablets) in Geriatric vs. Younger Patients. 9th World Congress on Pain, August 22-27, 1999, Vienna, Austria, p. 362.
  88. Spyker, D, Karpow, S, Munera, C, Zalman, MA, Wright, C, Reder, R, Hale, ME.  Transdermal Buprenorphine System (BTDS):  In Patient-Controlled Analgesia (PCA).  Clin Pharmacol Ther 16 (2):145, 2000
  89. McCroskery, E, Mullins, U, Haskell, L, and Reder, R.  Safety and Tolerance of Controlled-Release OxyContin® in the Immediate Post-Operative Period.  J Clin Pharmacol 2000;40:1045-1065.
  90. McCroskery, E, Croft, J, Markenson, J, Haskell, L, Mullins, U, and Reder, R.  3-Month Efficacy and Safety Study of OxyContin® in Osteoarthritis Patients.  EFIC 2000, Nice, France, September 26-29, 2000, p. 263.
  91. Reidenberg, B, Eltahtawy, A, Miller, J, Cipriano, A, Tonelli, A, Reder, R.  Pharmacokinetics and Safety of Buprenorphine Transdermal System (BTDS) for 7 Day Application Comprising 4 Different Body Sites on Healthy Adult Subjects.  America Pain Society 19th Annual Scientific Meeting, November 2-5, 2000, Atlanta, GA, p. 166.
  92. McCroskery, E, Haskell, L, Mullins, U, Reder, R.  Effectiveness of OxyContin in Osteoarthritis Patients with Uncontrolled Pain Measured by the Brief Pain Inventory.  American Pain Society 19th Annual Scientific Meeting, November 2-5, 2000, Atlanta, GA, p. 89.
  93. Hoffman, D L, Mueller, C, Reder, R, Richards, P. Dukes, E.  Burden of moderate-to-severe pain due to osteoarthritis: Impact on patient-reported health outcomes and health care utilization.  American Pain Society 20th Annual Scientific Meeting, April 19-22, 2001, Phoenix, AZ  Poster #712
  94. Zautra AJ, Smith BW, Mihalik MC, Reder R.  Effectiveness of Controlled-Resease OxyContin® on Cognitive-Behavioural Dimensions of Quality of Life in Osteoarthritis Patients with Uncontrolled Pain. American Pain Society 20th Annual Scientific Meeting, April 19-22, 2001, Phoenix, AZ  Poster #795  
  95. Blumer JL, Vashi VI, Ganesan R, Buice R, Richards P, Mihalik CM, Reder R.  Pharmacokinetics and Safety of Single-Dose Oral Administration of Controlled-Release Oxycodone (OxyContin®) and Immediate-Release Oxycodone in Children.  American Pain Society 20th Annual Scientific Meeting, April 19-22, 2001, Phoenix, AZ  Poster #783
  96. Lasseter KC, Venitz J, Eltahtawy A, Miotto J, Munera C, Reder R, Reidenberg BE.  Systemic pharmacokinetic (PK) study of Buprenorphine (B) in mild to moderate chronic hepatic impairment (CH)  Clinical Pharmacology & Therapeutics 2001: 69(2);  p. 2.
  97. Reidenberg BE, Eltahtawy A, Munera C, Cipriano A, Tonelli A, Reder RF: Pharmacokinetics and Safety of Buprenorphine Transdermal System (BRDS) for 7-day Application in Healthy Elderly and Young Adult Subjects.  J. Clin. Pharmacology 2001; 41:1029
  98. Reidenberg BE, Breder CD, Eltahtawy A, Creanga D, Miotto J, Reder RF: Physiologic Effects of Transdermal System (BTDS) Dose Esclation in the Young, Healthy Elderly and Elderly Hypertensive Subjects.  J. Clin. Pharmacology 2001; 41:1028
  99. Reidenberg BE, Eltahtawy A, Munera C, Cipriano A, Tonelli A, Reder, RF: Daily Pharmacokinetic Performance of a Buprenorphine Transdermal System (BRDS) for up to 7 Days. J. Clin. Pharmacology 2001; 41:1027
  100. Reidenberg BE, Eltahtawy A, Munera C, Cipriano A, Tonelli A, Reder, RF: Absolute Bioavailability of a Novel Buprenorphine Transdermal System (BTDS) Applied for 7 Days. J. Clin. Pharmacology 2001; 41:1026
  101. Lasseter KC, Venitz J, Eltahtawy A, Miotto J, Munera C, Reder RF, Reidenberg B:  Systemic Pharmacokinetic (PK) Study of Buprenorphine (B) in Mild to Moderate Chronic Hepatic Impairment (CHI).  J. Clin. Pharmacology 2001; 41:1028
  102. Blumer J, Vashi V, Ganesan R, Buice R, Richards P, Mihalik C, Reder R: Pharmacokinetics and safety of single-dose administration of controlled-release oxycodone (OxyContin) and immediate-release oxycodone in children.   Rainbow Babies and Children’s Hospital, Cleveland, OH; Purdue Pharma LP. Stamford CT   J. Pain 2001; 2(2) Supple 1:41
  103. Haddox JD, Cone E, Fant R, Rohay Y, Caplan, M, Ballina M, Reder R, Spyker D:  Oxycodone Involvement in Deaths from Drug Abuse Using a DAWN-Based Classification System.  The Journal of Pain 2003; 4(2):S3
  104. Haddox JD, Cone EJ, Fant RV, Caplan YH, Reder RF, Ballina M: Evidence for toxic drug-drug interactions in drug abuse deaths involving oxycodone.  The 2nd Joint Scientific Meeting of APS and CPS, 05/06/2004-05/09/2004, Vancouver, BC, Canada
  105. Cone EJ, Fant RV, Rhay JM, Caplan YH, Ballina M, Reder RF: Oxycodone Involvement in Drug Abuse Deaths, II. Evidence for Toxic Multiple Drug-Drug Iteractions.  Journal of Analytical Toxicology 2004; 28:217
  106. Buckley BJ, Xia Y, Reder RF: Extended-Release Hydromorphone Administered Every 24 Hours in The Elderly, AMDA 2004           
  107. Reder RF, Ballal S, Steiner D, Landau C:  Evaluation of the Safety and Efficacy of Hydromorphone HCl Extended-Release and Fentanyl Transdermal System in Subjects with Persistent Moderate to Severe Nonmalignant Pain.  American Academy of Pain Medicine, 2006
  108. Scholten W, Reder R:  WHO:  Changing the Guidelines to Improve Patient Access to Controlled Medications.  IASP, 2008, Glasgow, Scotland
  109. Roman X, Barch D, Bano K, Reder R: An Approach to Aggregate Safety Reporting of Drug and Device Constituent Parts of Combination Products. DIA, Washington D.C., June 14-18, 2015.
  110. Reder RF, Naylor S, Bano K:  Safety Surveillance of Scientific Literature Related to Combination Products.  DIA, Ottawa, Canada, October 26-28, 2015.

Home

About

Services

ARTICLES

Contact